603 / 1631
Efficacy
•
20 evaluable for response
•
ORR was 65%
(CR N=10/PR N=3)
•
CR rate was 50%
•
3 patients with stable disease and 4 with
progressive disease as best response
0
50
100
ORR SD PD
PD
SD
PR
CR
Time to Response
Best Response
Nastoupil L. et al. ASCO 2017